Hannant ME

References (1)

Title : Pharmacokinetics and pharmacodynamics of metrifonate in humans - Unni_1994_Meth.Find.Exp.Clin.Pharmacol_16_285
Author(s) : Unni LK , Womack C , Hannant ME , Becker RE
Ref : Methods Find Exp Clin Pharmacol , 16 :285 , 1994
Abstract : We studied the pharmacokinetics and pharmacodynamics [red blood cell (RBC) cholinesterase (ChE) inhibition] of metrifonate (MTF) and its active anti-ChE metabolite, dichlorvos (DDVP) in Alzheimer's disease (AD) patients and normal controls after oral MTF. In Study I conducted for 6 h, 3 patients with prior MTF exposure received oral MTF (7.5 mg/kg). Plasma ChE inhibition peaked to 78.5 +/- 12.3% at 15 min, while maximum RBC ChE inhibition seen at 1 h was 61.0 +/- 11.0%. Plasma ChE inhibition was unchanged at 6 h, whereas RBC ChE recovered with a t1/2 of 7.0 +/- 3.5 h. In Study II, 6 patients and 6 controls with no prior MTF exposure were given oral MTF. Mean plasma t1/2 of MTF was 2.3 +/- 0.3 h with ChE recovery t1/2 of 9.0 +/- 3.3 (plasma) and 26.6 +/- 15.2 days (RBC) after 7.5 mg/kg MTF. The short drug t1/2, long ChE recovery t1/2 and the achievement of high ChE inhibition levels with minimal side effects suggest the potential use of this drug for Alzheimer therapy.
ESTHER : Unni_1994_Meth.Find.Exp.Clin.Pharmacol_16_285
PubMedSearch : Unni_1994_Meth.Find.Exp.Clin.Pharmacol_16_285
PubMedID: 8051989